[Form 4] EXACT SCIENCES CORP Insider Trading Activity

Rhea-AI Filing Summary

Director sale under 10b5-1 plan: A director of Exact Sciences Corp. (EXAS) sold 2,000 shares of common stock on 10/09/2025 at a price of $60 per share under a Rule 10b5-1 trading plan established on 03/09/2025. After the transaction the reporting person beneficially owned 57,962 shares. The sale was reported on a Form 4 executed by an attorney-in-fact. This filing discloses a single routine disposition by an insider using a pre-established plan and does not include other derivative or non-derivative transactions.

Positive

• Sale executed under a Rule 10b5-1 plan, which provides an affirmative defense and indicates pre-arranged compliance
• Reporting person retains 57,962 shares after the sale, maintaining a meaningful stake

Negative

• None.

Insights

Compliance & Governance Analyst

Insider sale executed under a documented 10b5-1 plan, indicating routine compliance.

The transaction was a disposition of 2,000 shares executed on 10/09/2025 under a Rule 10b5-1 plan put in place on 03/09/2025. Using an established plan generally provides an affirmative defense against insider trading claims when the plan meets the rule's conditions.

Monitor whether additional filings show pattern changes in timing or size over the next 3-6 months; recurring large sales outside plans or sales that materially reduce holdings would be more consequential to governance and market perception.

Equity Holdings Analyst

Remaining stake stays substantial after the sale, suggesting limited immediate change to insider ownership.

Following the reported sale the reporting person holds 57,962 shares. The single 2,000-share sale represents a small portion of that position and therefore does not indicate a major change in insider ownership concentration.

Investors may track subsequent Form 4 filings to see if further dispositions occur; absent further sales, the current filing appears routine and non-material to overall ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle James Edward

(Last) (First) (Middle)

EXACT SCIENCES CORP.

5505 ENDEAVOR LANE

(Street)

MADISON WI 53719

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXACT SCIENCES CORP [ EXAS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/09/2025		S		2,000(1)	D	$60	57,962	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2025.

	/s/ James Edward Doyle by Mark Busch, attorney-in- fact	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the EXAS director sell on 10/09/2025?

The director sold 2,000 shares of Exact Sciences common stock at $60 per share on 10/09/2025.

Was the sale part of a 10b5-1 trading plan (EXAS)?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan entered into on 03/09/2025.

How many EXAS shares does the reporting person own after the transaction?

The reporting person beneficially owned 57,962 shares following the reported sale.

Does the Form 4 show any derivative transactions for EXAS?

No. The Form 4 lists only a non-derivative disposition of common stock and no derivative securities.

Who signed the Form 4 for the reporting person?

The Form 4 was signed on behalf of the reporting person by an attorney-in-fact, Mark Busch.